Taylor W. Foreman
Tulane University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Taylor W. Foreman.
Nature Communications | 2015
Deepak Kaushal; Taylor W. Foreman; Uma S. Gautam; Xavier Alvarez; Toidi Adekambi; Javier Rangel-Moreno; Nadia A. Golden; Ann-Marie Johnson; Bonnie L. Phillips; Muhammad H. Ahsan; Kasi Russell-Lodrigue; Lara A. Doyle; Chad J. Roy; Peter J. Didier; James Blanchard; Jyothi Rengarajan; Andrew A. Lackner; Shabaana A. Khader; Smriti Mehra
Tuberculosis (TB) is a global pandaemic, partially due to the failure of vaccination approaches. Novel anti-TB vaccines are therefore urgently required. Here we show that aerosol immunization of macaques with the Mtb mutant in SigH (MtbΔsigH) results in significant recruitment of inducible bronchus-associated lymphoid tissue (iBALT) as well as CD4+ and CD8+ T cells expressing activation and proliferation markers to the lungs. Further, the findings indicate that pulmonary vaccination with MtbΔsigH elicited strong central memory CD4+ and CD8+ T-cell responses in the lung. Vaccination with MtbΔsigH results in significant protection against a lethal TB challenge, as evidenced by an approximately three log reduction in bacterial burdens, significantly diminished clinical manifestations and granulomatous pathology and characterized by the presence of profound iBALT. This highly protective response is virtually absent in unvaccinated and BCG-vaccinated animals after challenge. These results suggest that future TB vaccine candidates can be developed on the basis of MtbΔsigH.
American Journal of Respiratory and Critical Care Medicine | 2015
Smriti Mehra; Taylor W. Foreman; Peter J. Didier; Muhammad H. Ahsan; Teresa A. Hudock; Ryan S. Kissee; Nadia A. Golden; Uma Shankar Gautam; Ann-Marie Johnson; Xavier Alvarez; Kasi Russell-Lodrigue; Lara A. Doyle; Chad J. Roy; Tianhua Niu; James Blanchard; Shabaana A. Khader; Andrew A. Lackner; David R. Sherman; Deepak Kaushal
RATIONALE Hypoxia promotes dormancy by causing physiologic changes to actively replicating Mycobacterium tuberculosis. DosR controls the response of M. tuberculosis to hypoxia. OBJECTIVES To understand DosRs contribution in the persistence of M. tuberculosis, we compared the phenotype of various DosR regulon mutants and a complemented strain to M. tuberculosis in macaques, which faithfully model M. tuberculosis infection. METHODS We measured clinical and microbiologic correlates of infection with M. tuberculosis relative to mutant/complemented strains in the DosR regulon, studied lung pathology and hypoxia, and compared immune responses in lung using transcriptomics and flow cytometry. MEASUREMENTS AND MAIN RESULTS Despite being able to replicate initially, mutants in DosR regulon failed to persist or cause disease. On the contrary, M. tuberculosis and a complemented strain were able to establish infection and tuberculosis. The attenuation of pathogenesis in animals infected with the mutants coincided with the appearance of a Th1 response and organization of hypoxic lesions wherein M. tuberculosis expressed dosR. The lungs of animals infected with the mutants (but not the complemented strain) exhibited early transcriptional signatures of T-cell recruitment, activation, and proliferation associated with an increase of T cells expressing homing and proliferation markers. CONCLUSIONS Delayed adaptive responses, a hallmark of M. tuberculosis infection, not only lead to persistence but also interfere with the development of effective antituberculosis vaccines. The DosR regulon therefore modulates both the magnitude and the timing of adaptive immune responses in response to hypoxia in vivo, resulting in persistent infection. Hence, DosR regulates key aspects of the M. tuberculosis life cycle and limits lung pathology.
Tuberculosis | 2015
Bianca R. Mothé; Cecilia S. Lindestam Arlehamn; Courtney Dow; Myles B.C. Dillon; Roger W. Wiseman; Patrick S. Bohn; Julie A. Karl; Nadia A. Golden; Trey Gilpin; Taylor W. Foreman; Mark A. Rodgers; Smriti Mehra; Thomas J. Scriba; JoAnne L. Flynn; Deepak Kaushal; David H. O'Connor; Alessandro Sette
Non-human primate (NHP) models of tuberculosis (TB) immunity and pathogenesis, especially rhesus and cynomolgus macaques, are particularly attractive because of the high similarity of the human and macaque immune systems. However, little is known about the MHC class II epitopes recognized in macaques, thus hindering the establishment of immune correlates of immunopathology and protective vaccination. We characterized immune responses in rhesus macaques vaccinated against and/or infected with Mycobacterium tuberculosis (Mtb), to a panel of antigens currently in human vaccine trials. We defined 54 new immunodominant CD4(+) T cell epitopes, and noted that antigens immunodominant in humans are also immunodominant in rhesus macaques, including Rv3875 (ESAT-6) and Rv3874 (CFP10). Pedigree and inferred restriction analysis demonstrated that this phenomenon was not due to common ancestry or inbreeding, but rather presentation by common alleles, as well as, promiscuous binding. Experiments using a second cohort of rhesus macaques demonstrated that a pool of epitopes defined in the previous experiments can be used to detect T cell responses in over 75% of individual monkeys. Additionally, 100% of cynomolgus macaques, irrespective of their latent or active TB status, responded to rhesus and human defined epitope pools. Thus, these findings reveal an unexpected general repertoire overlap between MHC class II epitopes recognized in both species of macaques and in humans, showing that epitope pools defined in humans can also be used to characterize macaque responses, despite differences in species and antigen exposure. The results have general implications for the evaluation of new vaccines and diagnostics in NHPs, and immediate applicability in the setting of macaque models of TB.
Proceedings of the National Academy of Sciences of the United States of America | 2016
Taylor W. Foreman; Smriti Mehra; Denae N. LoBato; Adel Malek; Xavier Alvarez; Nadia A. Golden; Allison N. Bucsan; Peter J. Didier; Lara A. Doyle-Meyers; Kasi Russell-Lodrigue; Chad J. Roy; James F. Blanchard; Marcelo J. Kuroda; Andrew A. Lackner; John Chan; Shabaana A. Khader; William R. Jacobs; Deepak Kaushal
Significance According to the World Health Organization, one in three humans is latently infected with Mycobacterium tuberculosis and 10% of these individuals risk developing active, clinical tuberculosis (TB) over their lifetimes. Coinfection with human immunodeficiency virus increases this risk substantially, with depletion of CD4+ T cells believed to drive disease progression. Although a minority of coinfected individuals can control the infection, the mechanisms underlying this phenomenon remain unknown. Modeling coinfection using macaques, we discovered that one-third of the animals maintained latency despite complete ablation of lung CD4+ T cells. We report that protective immune responses mediated by CD8+ T cells and B cells correlate with TB control. These findings have important implications in development of both prophylactic and therapeutic measures against TB and acquired immunodeficiency syndrome. The synergy between Mycobacterium tuberculosis (Mtb) and HIV in coinfected patients has profoundly impacted global mortality because of tuberculosis (TB) and AIDS. HIV significantly increases rates of reactivation of latent TB infection (LTBI) to active disease, with the decline in CD4+ T cells believed to be the major causality. In this study, nonhuman primates were coinfected with Mtb and simian immunodeficiency virus (SIV), recapitulating human coinfection. A majority of animals exhibited rapid reactivation of Mtb replication, progressing to disseminated TB and increased SIV-associated pathology. Although a severe loss of pulmonary CD4+ T cells was observed in all coinfected macaques, a subpopulation of the animals was still able to prevent reactivation and maintain LTBI. Investigation of pulmonary immune responses and pathology in this cohort demonstrated that increased CD8+ memory T-cell proliferation, higher granzyme B production, and expanded B-cell follicles correlated with protection from reactivation. Our findings reveal mechanisms that control SIV- and TB-associated pathology. These CD4-independent protective immune responses warrant further studies in HIV coinfected humans able to control their TB infection. Moreover, these findings will provide insight into natural immunity to Mtb and will guide development of novel vaccine strategies and immunotherapies.
Science immunology | 2017
Catherine Youting Cheng; Nuria Martinez Gutierrez; Mardiana Marzuki; Xiaohua Lu; Taylor W. Foreman; Bhairav S. Paleja; Bernett Lee; Akhila Balachander; Jinmiao Chen; Liana Tsenova; Natalia Kurepina; Karen W.W. Teng; Kim West; Smriti Mehra; Francesca Zolezzi; Michael Poidinger; Barry Kreiswirth; Deepak Kaushal; Hardy Kornfeld; Evan W. Newell; Amit Singhal
Sirtuin 1 activation decreases lung pathology, reduces inflammation, and enhances drug efficacy against Mycobacterium tuberculosis. Mtb faces sirtuin death Mycobacterium tuberculosis (Mtb) is the poster child for drug resistance, and new therapies are needed to combat this reemerging infection. Now, Cheng et al. report that Mtb infection down-regulates sirtuin 1, a NAD+-dependent deacetylase, in myeloid cells in animal models and patients with active disease. Activating sirtuin 1 inhibited intracellular growth of Mtb and persistent inflammatory responses, decreasing lung pathology. Sirtuin 1 activation also enhanced the efficacy of a first-line antituberculosis drug. These effects may be due, in part, to myeloid cell modulation, because mice with myeloid cell–specific SIRT1 deficiency had both increased inflammation and higher susceptibility to infection than wild-type controls. Thus, sirtuin 1 may be a target for host-directed therapy for Mtb. Mycobacterium tuberculosis (Mtb) executes a plethora of immune-evasive mechanisms, which contribute to its pathogenesis, limited efficacy of current therapy, and the emergence of drug-resistant strains. This has led to resurgence in attempts to develop new therapeutic strategies/targets against tuberculosis (TB). We show that Mtb down-regulates sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD+)–dependent deacetylase, in monocytes/macrophages, TB animal models, and TB patients with active disease. Activation of SIRT1 reduced intracellular growth of drug-susceptible and drug-resistant strains of Mtb and induced phagosome-lysosome fusion and autophagy in a SIRT1-dependent manner. SIRT1 activation dampened Mtb-mediated persistent inflammatory responses via deacetylation of RelA/p65, leading to impaired binding of RelA/p65 on the promoter of inflammatory genes. In Mtb-infected mice, the use of SIRT1 activators ameliorated lung pathology, reduced chronic inflammation, and enhanced efficacy of anti-TB drug. Mass cytometry–based high-dimensional analysis revealed that SIRT1 activation mediated modulation of lung myeloid cells in Mtb-infected mice. Myeloid cell–specific SIRT1 knockout mice display increased inflammatory responses and susceptibility to Mtb infection. Collectively, these results provide a link between SIRT1 activation and TB pathogenesis and indicate a potential of SIRT1 activators in designing an effective and clinically relevant host-directed therapies for TB.
Proceedings of the National Academy of Sciences of the United States of America | 2018
Uma S. Gautam; Taylor W. Foreman; Allison N. Bucsan; Ashley V. Veatch; Xavier Alvarez; Toidi Adekambi; Nadia A. Golden; Kaylee M. Gentry; Lara A. Doyle-Meyers; Kasi Russell-Lodrigue; Peter J. Didier; James Blanchard; K. Gus Kousoulas; Andrew A. Lackner; Daniel Kalman; Jyothi Rengarajan; Shabaana A. Khader; Deepak Kaushal; Smriti Mehra
Significance Mycobacterium tuberculosis induces the expression of the indoleamine 2,3-dioxygenase (IDO) enzyme, which catabolizes tryptophan. Tryptophan metabolites potently suppress host immunity. The present study demonstrates that blockade of IDO activity reduces both clinical manifestations of tuberculosis (TB) as well as microbial and pathological correlates of the human TB syndrome in macaques. In granulomas, T cells localize in the periphery, and are unable to access the core, where bacilli persist. Inhibiting IDO activity altered granuloma organization such that more T cells translocated to the lesion core and exhibited highly proliferative signatures. Our results identify a highly efficient immunosuppressive mechanism at play in the granuloma environment that aids in M. tuberculosis persistence. The ability to modulate this pathway with safe and approved compounds could, however, facilitate chemotherapy-adjunctive host-directed therapy approaches for the control of TB. Mycobacterium tuberculosis continues to cause devastating levels of mortality due to tuberculosis (TB). The failure to control TB stems from an incomplete understanding of the highly specialized strategies that M. tuberculosis utilizes to modulate host immunity and thereby persist in host lungs. Here, we show that M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in tryptophan catabolism, in macrophages and in the lungs of animals (mice and macaque) with active disease. In a macaque model of inhalation TB, suppression of IDO activity reduced bacterial burden, pathology, and clinical signs of TB disease, leading to increased host survival. This increased protection was accompanied by increased lung T cell proliferation, induction of inducible bronchus-associated lymphoid tissue and correlates of bacterial killing, reduced checkpoint signaling, and the relocation of effector T cells to the center of the granulomata. The enhanced killing of M. tuberculosis in macrophages in vivo by CD4+ T cells was also replicated in vitro, in cocultures of macaque macrophages and CD4+ T cells. Collectively, these results suggest that there exists a potential for using IDO inhibition as an effective and clinically relevant host-directed therapy for TB.
American Journal of Respiratory Cell and Molecular Biology | 2017
Teresa A. Hudock; Taylor W. Foreman; Nirmalya Bandyopadhyay; Uma S. Gautam; Ashley V. Veatch; Denae N. LoBato; Kaylee M. Gentry; Nadia A. Golden; Amy Cavigli; Michelle Mueller; Shen An Hwang; Robert L. Hunter; Xavier Alvarez; Andrew A. Lackner; Joel S. Bader; Smriti Mehra; Deepak Kaushal
&NA; Although it is accepted that the environment within the granuloma profoundly affects Mycobacterium tuberculosis (Mtb) and infection outcome, our ability to understand Mtb gene expression in these niches has been limited. We determined intragranulomatous gene expression in human‐like lung lesions derived from nonhuman primates with both active tuberculosis (ATB) and latent TB infection (LTBI). We employed a non‐laser‐based approach to microdissect individual lung lesions and interrogate the global transcriptome of Mtb within granulomas. Mtb genes expressed in classical granulomas with central, caseous necrosis, as well as within the caseum itself, were identified and compared with other Mtb lesions in animals with ATB (n = 7) or LTBI (n = 7). Results were validated using both an oligonucleotide approach and RT‐PCR on macaque samples and by using human TB samples. We detected approximately 2,900 and 1,850 statistically significant genes in ATB and LTBI lesions, respectively (linear models for microarray analysis, Bonferroni corrected, P < 0.05). Of these genes, the expression of approximately 1,300 (ATB) and 900 (LTBI) was positively induced. We identified the induction of key regulons and compared our results to genes previously determined to be required for Mtb growth. Our results indicate pathways that Mtb uses to ensure its survival in a highly stressful environment in vivo. A large number of genes is commonly expressed in granulomas with ATB and LTBI. In addition, the enhanced expression of the dormancy survival regulon was a key feature of lesions in animals with LTBI, stressing its importance in the persistence of Mtb during the chronic phase of infection.
PLOS ONE | 2017
Bonnie L. Phillips; Uma Shankar Gautam; Allison N. Bucsan; Taylor W. Foreman; Nadia A. Golden; Tianhua Niu; Deepak Kaushal; Smriti Mehra; Gobardhan Das
CD4+ T-cell mediated Th1 immune responses are critical for immunity to TB. The immunomodulatory protein, lymphocyte activation gene-3 (LAG-3) decreases Th1-type immune responses in T-cells. LAG-3 expression is significantly induced in the lungs of macaques with active TB and correlates with increased bacterial burden. Overproduction of LAG-3 can greatly diminish responses and could lead to uncontrolled Mtb replication. To assess the effect of LAG-3 on the progression of Mtb infection, we developed a co-culture system wherein blood-derived macrophages are infected with Mtb and supplemented with macaque blood or lung derived CD4+ T-cells. Silencing LAG-3 signaling in macaque lung CD4+ T-cells enhanced killing of Mtb in co-cultures, accompanied by reduced mitochondrial electron transport and increased IFN-γ expression. Thus, LAG-3 may modulate adaptive immunity to Mtb infection by interfering with the mitochondrial apoptosis pathway. Better understanding this pathway could allow us to circumvent immune features that promote disease.
Ilar Journal | 2017
Taylor W. Foreman; Smriti Mehra; Andrew A. Lackner; Deepak Kaushal
Infection with Mycobacterium tuberculosis predominantly establishes subclinical latent infection over the lifetime of an individual, with a fraction of infected individuals rapidly progressing to active disease. The immune control in latent infection can be perturbed by comorbidities such as diabetes mellitus, obesity, smoking, and coinfection with helminthes or HIV. Modeling the varying aspects of natural infection remains incomplete when using zebrafish and mice. However, the nonhuman primate model of tuberculosis offers a unique and accurate model to investigate host responses to infection, test novel therapeutics, and thoroughly assess preclinical vaccine candidates. Rhesus macaques and cynomolgus macaques manifest the full gamut of clinical and pathological findings in human Mycobacterium tuberculosis infection, including the ability to co-infect macaques with Simian Immunodeficiency Virus to model HIV co-infection. Here we discuss advanced techniques to assay various clinical outcomes of the natural progression of infection as well as therapeutics in development and novel preclinical vaccines. Finally, we survey the translational aspects of nonhuman primate research and argue the urgent need to thoroughly examine preclinical therapeutics and vaccines using this model prior to clinical implementation.
Nature microbiology | 2018
Michelle A. Sallin; Keith D. Kauffman; Catherine Riou; Elsa du Bruyn; Taylor W. Foreman; Shunsuke Sakai; Stella G. Hoft; Timothy G. Myers; Paul J. Gardina; Alan Sher; Rashida Moore; Temeri Wilder-Kofie; Ian N. Moore; Alessandro Sette; Cecilia S. Lindestam Arlehamn; Robert J. Wilkinson; Daniel L. Barber
Mycobacterium tuberculosis infection (Mtb) is the leading cause of death due to a single infectious agent and is among the top ten causes of all human deaths worldwide1. CD4 T cells are essential for resistance to Mtb infection, and for decades it has been thought that IFNγ production is the primary mechanism of CD4 T-cell-mediated protection2,3. However, IFNγ responses do not correlate with host protection, and several reports demonstrate that additional anti-tuberculosis CD4 T-cell effector functions remain unaccounted for4–8. Here we show that the tumour-necrosis factor (TNF) superfamily molecule CD153 (encoded by the gene Tnfsf8) is required for control of pulmonary Mtb infection by CD4 T cells. In Mtb-infected mice, CD153 expression is highest on Mtb-specific T helper 1 (TH1) cells in the lung tissue parenchyma, but its induction does not require TH1 cell polarization. CD153-deficient mice develop high pulmonary bacterial loads and succumb early to Mtb infection. Reconstitution of T-cell-deficient hosts with either Tnfsf8−/− or Ifng−/− CD4 T cells alone fails to rescue mice from early mortality, but reconstitution with a mixture of Tnfsf8−/− and Ifng−/− CD4 T cells provides similar protection as wild-type T cells. In Mtb-infected non-human primates, CD153 expression is much higher on Ag-specific CD4 T cells in the airways compared to blood, and the frequency of Mtb-specific CD153-expressing CD4 T cells inversely correlates with bacterial loads in granulomas. In Mtb-infected humans, CD153 defines a subset of highly polyfunctional Mtb-specific CD4 T cells that are much more abundant in individuals with controlled latent Mtb infection compared to those with active tuberculosis. In all three species, Mtb-specific CD8 T cells did not upregulate CD153 following peptide stimulation. Thus, CD153 is a major immune mediator of host protection against pulmonary Mtb infection and CD4 T cells are one important source of this molecule.CD153 expression by CD4 T cells is required for control of pulmonary Mycobacterium tuberculosis infection.